Publications

Export 188 results:
Sort by: [ Author  (Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Z
Zekri, A. - R., H. Shousha, A. Nassar, N. Zayed, G. Esmat, A. Abdel-Aziz, and A. Kaseb. "GENE METHYLATION MARKERS FOR EGYPTIAN PATIENTS WITH HEPATOCELLULAR CARCINOMA." JOURNAL OF HEPATOLOGY 58 (2013): S256. Abstract
n/a
Zekri, Abdel-Rahman N., Rabab A. N. Moharram, Waleed S. Mohamed, Abeer A. Bahnassy, Hanaa Alam M. El-Din, Maha M. Abo-Shadi, Naglaa A. Zayed, Husseim El-Magzangy, Ashraf O. Abdel-Aziz, and Gamal Esmat. "Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with repression of interferon regulatory factor-1." EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY 22 (2010): 450-456. Abstract
n/a
Zekri, A., S. Zakaria, G. Esmat, H. A. El-Din, M. Hafez, and A. Farouk. "Serum concentrations of IL-2R, IL-6R, IL-8, TNFR-i, TNFR-II, sFas, and sFas-L in CAH patients: pre- and post-IFN treatment." LIVER INTERNATIONAL 26 (2006): 63-64. Abstract
n/a
Zekri, A. R. N., H. A. Haleem, G. E. - D. Esmat, A. A. Bahnassy, H. M. A. El-Din, M. M. Hafez, A. F. Sharaby, H. Sharaf, and M. S. E. - D. Zakaria. "Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4." JOURNAL OF VIRAL HEPATITIS 14 (2007): 468-477. Abstract
n/a
Zayed, Naglaa, Gamal Esmat, Wafaa A. ElAkel, Tahany Awad, and Mahasen Mabrouk. "Therapeutic Outcome in 6198 Interferon-Naive Egyptian Patients with Chronic Hepatitis C genotype-4: A Real Experience." HEPATOLOGY 56 (2012): 1016A. Abstract
n/a
Zaky, Samy, Mohamed Alboraie, Mohamed Elbadry, Mohamed A. Metwally, Ahmed Abdelaziz, Yasser Fouad, Sherief Abd-Elsalam, Abdelmajeed Mahmoud, Gamal Shiha, Amin Abdel Baki et al. "Management of liver disease patients in different clinical situations during COVID-19 pandemic." Egyptian liver journal 11, no. 1 (2021): 21. Abstract

Chronic liver diseases are common worldwide, especially in developing countries. The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/(COVID-19) leads to the infection of many patients with underlying chronic liver diseases. As a relatively new disease, management of COVID-19, in the context of chronic liver disease, is mainly based on the experience of the treating physician and the available data. In this review, we summarize the available evidence about the management of liver disease patients, in the context of COVID-19 infection, which can increase the severity of viral hepatitis B. Also, its clearance in HBV patients is delayed. A sixfold increased severity of COVID-19 was reported in obese patients with metabolic associated fatty liver disease (MAFDL). In patients with autoimmune liver disease (AILD), it is not recommended to change their immunosuppressive therapy (as long as they are not infected with COVID-19), in order to avoid a flare of liver disease. However, immunosuppressant drugs should be modified, in the case of infection with COVID-19. To date, no data suggest an increased risk or severity in metabolic liver diseases, such as hemochromatosis, Wilson's disease, or alpha-1 antitrypsin deficiency. Patients with liver cirrhosis should be carefully managed with minimum exposure to healthcare facilities. Basic investigations for follow-up can be scheduled at wider intervals; if patients need admission, this should be in COVID-19-clean areas. Patients with hepatocellular carcinomas may have a poor prognosis according to preliminary reports from China. The course of COVID-19 in liver transplant recipients on immunosuppression seems to have a benign course, based on few reports in children and adults. The hepatotoxicity of COVID-19 drugs ranges from mild liver enzyme elevation to a flare of underlying liver diseases. Therefore, the decision should be customized. Telemedicine can minimize the exposure of healthcare workers and patients to infection with COVID-19 and decrease the consumption of personal protective equipment.

Zakhari, Samir, Gamal Esmat, and Scott Friedman. "Introduction to the Symposium." ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH 35 (2011): 775. Abstract
n/a
Zakaria, Soheir, Rabab Fouad, Olfat Shaker, Sami Zaki, Ahmed Hashem, Samer S. El-Kamary, Gamal Esmat, and Serag Zakaria. "Changing patterns of acute viral hepatitis at a major urban referral center in Egypt." CLINICAL INFECTIOUS DISEASES 44 (2007): E30-E36. Abstract
n/a
Zakaria, S., R. Fouad, O. Shaker, W. Elakel, A. Hashem, G. Esmat, and S. Zakaria. "Natural history of the untreated symptomatic acute hepatitis C infection in Egypt." LIVER INTERNATIONAL 26 (2006): 73. Abstract
n/a
Y
Yosry, A., G. Esmat, A. Omar, M. El-Serafy, W. Doss, A. El-Tawil, A. Ghaly, R. Kamel, H. Khalil, H. El-Gabaly et al. "Pretransplantation MELD score does not predict recipient survival in adult living donor liver transplantation (LDLT)." LIVER TRANSPLANTATION 12 (2006): C80. Abstract
n/a
Yosry, Ayman, Rabab F. Omar, Mohamed Ezz Al Arab, Hanan Abdel-Hafez, Mohamed Gohar, and Gamal Esmat. "Transient Elastography Can Predict the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C." HEPATOLOGY 56 (2012): 844A. Abstract
n/a
Yosry, A., W. Doss, A. Abdel-Bary, G. Esmat, M. El-Serafy, E. Omar, A. El-Tawil, A. Ghaly, A. Hosny, S. Rifaat et al. "Hepatitis C virus genotype 4 recurrence in Egyptian living donor liver transplant recipients." LIVER TRANSPLANTATION 11 (2005): C19. Abstract
n/a
Yosry, Ayman, Mohamed Said, Gamal Esmat, Magdy Al-Serafy, Ashraf Omar, Wahid Doss, Dalia Omran, Yasmin Saad, Sanna Kamel, Akram Abdel-Bary et al. "HLA Tissue Typing Has No Effect on the Outcome of Patients Undergoing a Living-donor Liver Transplant: A Single-center Experience in Egypt." EXPERIMENTAL AND CLINICAL TRANSPLANTATION 10 (2012): 136-140. Abstract
n/a
Yosry, Ayman, Mahasen Abdel-Rahman, Gamal Esmat, Magdy El-Serafy, Ashraf Omar, Waheed Doss, Nagla Zayed, Mohamed Said, Tamer Ismail, Adel Hosny et al. "Recurrence of Hepatitis C Virus (Genotype 4) Infection After Living-Donor Liver Transplant in Egyptian Patients." EXPERIMENTAL AND CLINICAL TRANSPLANTATION 7 (2009): 157-163. Abstract
n/a
Yosry, A., G. Esmat, M. El-Serafy, A. Omar, W. Doss, M. Said, A. Abdel-Bary, A. Hosny, I. Marawan, O. El-Malt et al. "Outcome of living donor liver transplantation for Egyptian patients with hepatitis C (genotype 4)-related cirrhosis." TRANSPLANTATION PROCEEDINGS 40 (2008): 1481-1484. Abstract
n/a
Yosry, A., A. EL-Hendawy, N. Zayed, M. EL-Neklawi, M. EL-Sahhar, A. EL-Taweel, and G. Esmat. "EXPRESSION OF CYCLOOXYGENASE-2 IN PATIENTS WITH HEPATITIS C VIRUS AND THE EFFECT OF INTERFERON/RIBAVIRIN THERAPY." JOURNAL OF HEPATOLOGY 50}, Meeting Abstract = {650 (2009): S239. Abstract
n/a
Yosry, A., Y. El-Sharif, A. Hendawi, G. Esmat, M. Salah, and S. Zakaria. "Hepatic cyclooxygenase (COX)-2 and response to combined Interferon & Ribavirin therapy in chronic hepatitis C." JOURNAL OF HEPATOLOGY 42 (2005): 228. Abstract
n/a
W
Wiersma, S. T., B. McMahon, J. M. Pawlotsky, C. L. Thio, M. Thursz, S. G. Lim, P. Ocama, G. Esmat, M. Mendy, D. Bell et al. "Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus (vol 31, pg 755, 2011)." LIVER INTERNATIONAL 32 (2012): 174. Abstract
n/a
Wedemeyer, H., A. S. Duberg, M. Buti, W. M. Rosenberg, S. Frankova, G. Esmat, N. Örmeci, H. Van Vlierberghe, M. Gschwantler, U. Akarca et al. "Strategies to manage hepatitis C virus (HCV) disease burden." Journal of viral hepatitis 21 Suppl 1 (2014): 60-89. Abstract

The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.

Waly, A., H. M. El Tayebi, K. A. Hosny, G. Esmat, and A. I. Abdelaziz. "HYPERMETHYLATION OF THE microRNA LET-7A-3 GENE REPRESSES THE PRIMARY AND MATURE LET-7A-3 WITH AN INVERSE CORRELATION TO IGF-II mRNA IN HCV-INDUCED HEPATOCELLULAR CARCINOMA." JOURNAL OF HEPATOLOGY 58 (2013): S448-S449. Abstract
n/a
Waked, Imam, Waheed Doss, Manal Hamdy El-Sayed, Chris Estes, Homie Razavi, Gamal Shiha, Ayman Yosry, and Gamal Esmat. "The current and future disease burden of chronic hepatitis C virus infection in Egypt." Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology 15, no. 2 (2014): 45-52. Abstract
n/a
WAHAB, MFA, and G. Esmat. "THE VALUE OF ULTRASONOGRAPHY IN ASSESSMENT OF PORTAL-HYPERTENSION IN HEPATOSPLENIC SCHISTOSOMIASIS." MEMORIAS DO INSTITUTO OSWALDO CRUZ 87 (1992): 143-147. Abstract
n/a
V
Vignier, N., G. Esmat, A. Elsharkawy, M. Hassany, P. Bonnard, E. Delarocque-Astagneau, M. Said, R. Raafat, M. El-Hoseiny, A. Fontanet et al. "Reproducibility of liver stiffness measurements in hepatitis C virus (HCV)-infected patients in Egypt." JOURNAL OF VIRAL HEPATITIS 18 (2011): E358-E365. Abstract
n/a
U
Umar, Muhammed, Aamir G. Khan, Zaigham Abbas, Sanjeev Arora, Naqvi Asifabbas, Andre Elewaut, Gamal Esmat, Graham Foster, Michael Fried, Khean-L Goh et al. "World Gastroenterology Organisation global guidelines: diagnosis, management and prevention of hepatitis C April 2013." Journal of clinical gastroenterology 48, no. 3 (2014): 204-17. Abstract
n/a
T
Tayel, Sara S., Amal A. Helmy, Rasha Ahmed, Gamal Esmat, Nabila Hamdi, and Ahmed Ihab Abdelaziz. "Progesterone suppresses interferon signaling by repressing TLR-7 and MxA expression in peripheral blood mononuclear cells of patients infected with hepatitis C virus." ARCHIVES OF VIROLOGY 158 (2013): 1755-1764. Abstract
n/a
Tourism